EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)

Ting Yang, Baiqiang Cai, Bin Cao, Jian Kang, Fuqiang Wen, Yahong Chen, Wenhua Jian, Chen Wang iD

Therapeutic Advances in Respiratory Disease · 2023

DOI: 10.1177/17534666231158283 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2023. Verfasst von Ting Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, National Clinical Research Centre for Respiratory Diseases, China-Japan Friendship Hospital, Beij…. Hauptthemen laut MEDLINE: Bronchodilator Agents, Pulmonary Disease, Chronic Obstructive. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Underdiagnosis and undertreatment pose major barriers to optimal management of chronic obstructive pulmonary disease (COPD) in China.

Objective

The REAL trial was performed to generate reliable information on real-world COPD management, outcomes and risk factors among Chinese patients. Here, we present study outcomes related to COPD management.

Design

It is a 52-week, prospective, observational, multicentre study.

Methods

Outpatients (aged ⩾40 years) enrolled from 50 secondary and tertiary hospitals across six geographic regions of China were followed up for 12 months, with two onsite visits and by telephone every 3 months following baseline.

Results

Between June 2017 and January 2019, 5013 patients were enrolled and 4978 included in the analysis. Mean [standard deviation (SD)] age was 66.2 (8.9) years, the majority of patients were male (79.5%) and mean (SD) time since COPD diagnosis was 3.8 (6.2) years. The most common treatments at each study visit were inhaled corticosteroids/long-acting beta-agonists (ICSs/LABAs; 28.3–36.0%), long-acting muscarinic antagonists (LAMAs; 13.0–16.2%) and ICS/LABA + LAMA (17.5–18.7%), but up to 15.8% of patients at each visit received neither ICS nor long-acting bronchodilators. The use of ICS/LABA, LAMA and ICS/LABA + LAMA differed across regions and hospital tiers; up to fivefold, more patients received neither ICS nor long-acting bronchodilators in secondary (17.3–25.4%) versus tertiary hospitals (5.0–5.3%). Overall, rates of nonpharmacological management were low. Direct treatment costs increased with disease severity, but the proportion of direct treatment costs incurred due to maintenance treatment decreased with disease severity.

Conclusion

ICS/LABA, LAMA and ICS/LABA + LAMA were the most frequently prescribed maintenance treatments for patients with stable COPD in China, although their use differed between region and hospital tier. There is a clear need for improved COPD management across China, particularly in secondary hospitals. Registration: The trial was registered on 20 March 2017 (ClinicalTrials.gov identifier: NCT03131362; https://clinicaltrials.gov/ct2/show/NCT03131362 ). Plain language summary Treatment patterns in patients with COPD in China Background: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease characterized by progressive and irreversible airflow limitation. In China, many patients with this disease do not receive a diagnosis or appropriate treatment.

Objective

This study aimed to generate reliable information on the treatment patterns among patients with COPD in China to help inform future management strategies. Study design and methods: Patients (aged ⩾40 years) were enrolled from 50 hospitals across 6 regions of China and physicians collected data over the course of 1 year during routine outpatient visits.

Results

The majority of patients were receiving long-acting inhaled treatments, which are recommended to prevent worsening of the disease. Up to 16% of patients in this study, however, did not receive any of these recommended treatments. The proportion of patients who received long-acting inhaled treatments differed across regions and hospital tiers; there were about five times more patients in secondary hospitals (about 25%) who did not receive these treatments compared with those in tertiary hospitals (about 5%). Guidelines recommend that pharmacological treatment should be complemented by nondrug treatment, but this was only received by a minority of patients in this study. Patients with higher disease severity incurred greater direct treatment costs compared with those with milder disease. Maintenance treatment costs made up a smaller proportion of overall direct costs for patients with higher disease severity (60–76%) compared with patients with milder disease (81–94%).

Conclusion

Long-acting inhaled treatments were the most frequently prescribed maintenance treatments among patients with COPD in China, but their use differed between region and hospital tier. There is a clear need to improve disease management across China, especially in secondary hospitals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchodilator AgentsPulmonary Disease, Chronic ObstructiveHumansMaleFemaleAgedProspective StudiesAdministration, InhalationCohort StudiesMuscarinic AntagonistsDrug Therapy, CombinationAdrenal Cortex HormonesAdrenergic beta-2 Receptor Agonists

Stichwörter der Autor:innen

COPDChinageographic regionhospital tierinhaled corticosteroidslong-acting bronchodilatormaintenance therapyobservational studytreatment patterns

Substanzen

Bronchodilator AgentsMuscarinic AntagonistsAdrenal Cortex HormonesAdrenergic beta-2 Receptor Agonists

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, National Clinical Research Centre for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.
  • Institute of Respiratory Medicine, Chinese Academy of Medical Science, Beijing, China.
  • Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China.
  • Department of Respiratory and Critical Care Medicine, The First Hospital of China Medical University, Shenyang, China.
  • Department of Respiratory and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.

ORCID-Profile: Chen Wang

Förderung

  • AstraZeneca China

Zitieren

APA

Yang, T., Cai, B., Cao, B., Kang, J., Wen, F., Chen, Y., Jian, W., & Wang, C. (2023). Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL). Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666231158283

Vancouver

Yang T, Cai B, Cao B, Kang J, Wen F, Chen Y, et al. Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL). Therapeutic Advances in Respiratory Disease. 2023. doi:10.1177/17534666231158283

BibTeX
@article{Yang2023,
  author = {Yang, Ting and Cai, Baiqiang and Cao, Bin and Kang, Jian and Wen, Fuqiang and Chen, Yahong and Jian, Wenhua and Wang, Chen},
  title = {Treatment patterns in patients with stable COPD in China: analysis of a prospective, 52-week, nationwide, observational cohort study (REAL)},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2023},
  doi = {10.1177/17534666231158283}
}
Kostenlos starten →